| Medical and Health Sciences | Lifetime | 108 | JP 1 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 11 | JP 1 | 100.00 |
| Hepatology | Lifetime | 2 | JP 1 | 99.98 |
| Epidemiology | Lifetime | 41 | JP 2 | 99.93 |
| Oncology | Lifetime | 115 | JP 2 | 99.80 |
| Surgery | Lifetime | 420 | JP 10 | 99.63 |
| Pathology and Forensic Medicine | Lifetime | 138 | JP 4 | 99.41 |
| Pulmonary and Respiratory Medicine | Lifetime | 403 | JP 11 | 99.48 |
| Cancer Research | Lifetime | 280 | JP 4 | 98.35 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 650 | JP 16 | 98.32 |
| Gastroenterology | Lifetime | 650 | JP 34 | 79.76 |
| Anesthesiology and Pain Medicine | Lifetime | 650 | JP 18 | 70.45 |
| Hepatology | 2021-2025 | 1 | JP 1 | 99.98 |
| Oncology | 2021-2025 | 20 | JP 1 | 99.89 |
| Epidemiology | 2021-2025 | 52 | JP 1 | 99.71 |
| Pathology and Forensic Medicine | 2021-2025 | 19 | JP 1 | 99.54 |
| Surgery | 2021-2025 | 119 | JP 3 | 99.31 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 121 | JP 8 | 99.19 |
| Cancer Research | 2021-2025 | 109 | JP 1 | 95.02 |
| Immunology | 2021-2025 | 455 | JP 10 | 87.43 |
| Rheumatology | 2021-2025 | 380 | JP 7 | 84.64 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 698 | JP 15 | 83.92 |
| Hepatocellular Carcinoma Treatment and Prognosis | Lifetime | 2 | JP 1 | 99.98 |
| Liver Disease Diagnosis and Treatment | Lifetime | 8 | JP 1 | 99.96 |
| Cancer Mechanisms and Therapy | Lifetime | 2 | JP 1 | 99.93 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 6 | JP 1 | 99.93 |
| Liver physiology and pathology | Lifetime | 6 | JP 1 | 99.85 |
| Ferroptosis and cancer prognosis | Lifetime | 9 | JP 1 | 99.69 |
| Hepatitis B Virus Studies | Lifetime | 24 | JP 2 | 99.88 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 26 | JP 1 | 99.87 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 35 | JP 1 | 99.89 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 63 | JP 1 | 99.72 |
| Colorectal Cancer Treatments and Studies | Lifetime | 33 | JP 1 | 99.81 |
| Cancer, Lipids, and Metabolism | Lifetime | 40 | JP 1 | 99.78 |
| MRI in cancer diagnosis | Lifetime | 31 | JP 1 | 99.56 |
| Hepatitis C virus research | Lifetime | 70 | JP 6 | 99.74 |
| Liver Disease and Transplantation | Lifetime | 71 | JP 3 | 99.72 |
| Renal cell carcinoma treatment | Lifetime | 117 | JP 1 | 99.29 |
| Lung Cancer Treatments and Mutations | Lifetime | 283 | JP 21 | 99.27 |
| Ultrasound and Hyperthermia Applications | Lifetime | 76 | JP 3 | 98.60 |
| Gastrointestinal disorders and treatments | Lifetime | 189 | JP 19 | 99.11 |
| Pancreatitis Pathology and Treatment | Lifetime | 185 | JP 21 | 98.89 |
| Gallbladder and Bile Duct Disorders | Lifetime | 199 | JP 33 | 98.97 |
| Gastric Cancer Management and Outcomes | Lifetime | 550 | JP 107 | 98.83 |
| IgG4-Related and Inflammatory Diseases | Lifetime | 43 | JP 17 | 97.95 |
| Pediatric Hepatobiliary Diseases and Treatments | Lifetime | 265 | JP 37 | 98.38 |
| Neuroendocrine Tumor Research Advances | Lifetime | 614 | JP 45 | 97.98 |
| Endoplasmic Reticulum Stress and Disease | Lifetime | 427 | JP 45 | 97.20 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 476 | JP 19 | 96.50 |
| Medical Imaging and Pathology Studies | Lifetime | 1,000 | JP 120 | 95.68 |
| Gastrointestinal Tumor Research and Treatment | Lifetime | 942 | JP 272 | 95.77 |
| Genetic and Kidney Cyst Diseases | Lifetime | 423 | JP 28 | 94.75 |
| Biliary and Gastrointestinal Fistulas | Lifetime | 388 | JP 43 | 94.62 |
| Multiple and Secondary Primary Cancers | Lifetime | 608 | JP 31 | 94.37 |
| Ultrasound Imaging and Elastography | Lifetime | 452 | JP 7 | 94.06 |
| Fibroblast Growth Factor Research | Lifetime | 746 | JP 72 | 91.69 |
| Tuberous Sclerosis Complex Research | Lifetime | 438 | JP 31 | 86.48 |
| Hepatocellular Carcinoma Treatment and Prognosis | 2021-2025 | 1 | JP 1 | 99.99 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 3 | JP 1 | 99.88 |
| Cancer Mechanisms and Therapy | 2021-2025 | 1 | JP 1 | 99.96 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 2 | JP 1 | 99.93 |
| Hepatitis B Virus Studies | 2021-2025 | 6 | JP 1 | 99.76 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 29 | JP 2 | 99.87 |
| Liver physiology and pathology | 2021-2025 | 2 | JP 1 | 99.78 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 10 | JP 3 | 99.84 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 33 | JP 2 | 99.82 |
| Hepatitis C virus research | 2021-2025 | 13 | JP 1 | 99.63 |
| Ferroptosis and cancer prognosis | 2021-2025 | 34 | JP 1 | 99.35 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 39 | JP 1 | 98.93 |
| Gastrointestinal disorders and treatments | 2021-2025 | 31 | JP 4 | 97.88 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 177 | JP 29 | 98.23 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 119 | JP 2 | 96.41 |
| Renal cell carcinoma treatment | 2021-2025 | 177 | JP 6 | 97.03 |
| Gallbladder and Bile Duct Disorders | 2021-2025 | 165 | JP 26 | 96.62 |
| Liver Disease and Transplantation | 2021-2025 | 299 | JP 10 | 96.99 |
| Cancer Genomics and Diagnostics | 2021-2025 | 989 | JP 35 | 94.41 |
| Pediatric Hepatobiliary Diseases and Treatments | 2021-2025 | 198 | JP 36 | 93.11 |
| Pancreatitis Pathology and Treatment | 2021-2025 | 370 | JP 31 | 93.23 |
| Immunotherapy and Immune Responses | 2021-2025 | 820 | JP 17 | 91.86 |
| Immune Response and Inflammation | 2021-2025 | 317 | JP 12 | 86.78 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 63 | JP 27 | 89.80 |
| NF-κB Signaling Pathways | 2021-2025 | 51 | JP 5 | 82.99 |
| Cancer Treatment and Pharmacology | 2021-2025 | 785 | JP 49 | 86.28 |
| Gastrointestinal Bleeding Diagnosis and Treatment | 2021-2025 | 643 | JP 103 | 70.15 |
| Wnt/β-catenin signaling in development and cancer | 2021-2025 | 362 | JP 22 | 64.27 |
